Abstract：
BACKGROUND: Recent data in nonpregnant individuals suggest a protective effect of influenza vaccination against SARS-CoV-2 infection and its severity.
OBJECTIVE: Our primary objective was to evaluate whether influenza vaccination was associated with COVID-19 severity and pregnancy and neonatal outcomes among those infected with SARS-CoV-2. The secondary objective was to examine the association between influenza vaccination and SARS-CoV-2 infection.
METHODS: Secondary analysis of a multicenter retrospective cohort of pregnant people who tested positive for SARS-CoV-2 between March and August 2020, and a cohort of random deliveries during the same time period. The associations between 2019 influenza vaccination and the primary outcome of moderate-to-critical COVID-19 as well as maternal and perinatal outcomes were examined among all people who tested positive for SARS-CoV-2 between March and August 2020. The association between 2019 influenza vaccination and having a positive SARS-CoV-2 test was examined among a cohort of individuals who delivered on randomly selected dates between March and August 2020. Univariable and multivariable analyses were performed.
RESULTS: Of 2325 people who tested positive for SARS-CoV-2, 1068 (45.9%) were vaccinated against influenza in 2019. Those who received the influenza vaccine were older, leaner, more likely to have private insurance, and identify as White or Hispanic. They were less likely to smoke tobacco and identify as Black. Overall, 419 (18.0%) had moderate, 193 (8.3%) severe, and 52 (2.2%) critical COVID-19. There was no association between influenza vaccination and moderate-to-critical COVID-19 (29.2% vs. 28.0%, adjusted OR 1.10, 95% CI 0.90-1.34) or adverse maternal and perinatal outcomes among those who tested positive. Of 8152 people who delivered in 2020, 4658 (57.1%) received the influenza vaccine. Prior vaccination was not associated with a difference in the odds of SARS-CoV-2 infection (3.8% vs. 4.2%, adjusted OR 0.94, 95% CI 0.74-1.19).
CONCLUSIONS: Prior influenza vaccination was not associated with decreased severity of COVID-19 or lower odds of SARS-CoV-2 infection in pregnancy.
OBJECTIVE: Our primary objective was to evaluate whether influenza vaccination was associated with COVID-19 severity and pregnancy and neonatal outcomes among those infected with SARS-CoV-2. The secondary objective was to examine the association between influenza vaccination and SARS-CoV-2 infection.
METHODS: Secondary analysis of a multicenter retrospective cohort of pregnant people who tested positive for SARS-CoV-2 between March and August 2020, and a cohort of random deliveries during the same time period. The associations between 2019 influenza vaccination and the primary outcome of moderate-to-critical COVID-19 as well as maternal and perinatal outcomes were examined among all people who tested positive for SARS-CoV-2 between March and August 2020. The association between 2019 influenza vaccination and having a positive SARS-CoV-2 test was examined among a cohort of individuals who delivered on randomly selected dates between March and August 2020. Univariable and multivariable analyses were performed.
RESULTS: Of 2325 people who tested positive for SARS-CoV-2, 1068 (45.9%) were vaccinated against influenza in 2019. Those who received the influenza vaccine were older, leaner, more likely to have private insurance, and identify as White or Hispanic. They were less likely to smoke tobacco and identify as Black. Overall, 419 (18.0%) had moderate, 193 (8.3%) severe, and 52 (2.2%) critical COVID-19. There was no association between influenza vaccination and moderate-to-critical COVID-19 (29.2% vs. 28.0%, adjusted OR 1.10, 95% CI 0.90-1.34) or adverse maternal and perinatal outcomes among those who tested positive. Of 8152 people who delivered in 2020, 4658 (57.1%) received the influenza vaccine. Prior vaccination was not associated with a difference in the odds of SARS-CoV-2 infection (3.8% vs. 4.2%, adjusted OR 0.94, 95% CI 0.74-1.19).
CONCLUSIONS: Prior influenza vaccination was not associated with decreased severity of COVID-19 or lower odds of SARS-CoV-2 infection in pregnancy.
摘要：
背景：非妊娠个体的最新数据表明，流感疫苗接种对SARS-CoV-2感染及其严重程度具有保护作用。
目的：我们的主要目的是评估SARS-CoV-2感染者的流感疫苗接种是否与COVID-19严重程度、妊娠和新生儿结局相关。次要目标是检查流感疫苗接种与SARS-CoV-2感染之间的关联。
方法：对2020年3月至8月间SARS-CoV-2阳性孕妇的多中心回顾性队列和同期随机分娩队列进行二次分析。在2020年3月至8月期间，所有SARS-CoV-2检测呈阳性的人中，检查了2019年流感疫苗接种与中危COVID-19的主要结局以及孕产妇和围产期结局之间的关系。在2020年3月至8月之间随机选择的日期交付的一组个体中，检查了2019年流感疫苗接种与SARS-CoV-2测试阳性之间的关联。进行单变量和多变量分析。
结果：在SARS-CoV-2检测呈阳性的2325人中，有1068人（45.9％）在2019年接种了流感疫苗。接种流感疫苗的人年龄较大，leaner,更有可能有私人保险，并识别为白人或西班牙裔。他们吸烟的可能性较小，被认定为黑人。总的来说,419（18.0%）中度，193（8.3％）严重，和52（2.2%）关键COVID-19。流感疫苗接种与中度至重度COVID-19之间没有关联(29.2%与28.0%,校正OR1.10，95％CI0.90-1.34）或检测阳性的产妇和围产期不良结局。在2020年交付的8152人中，有4658人（57.1％）接种了流感疫苗。先前的疫苗接种与SARS-CoV-2感染几率的差异无关(3.8%与4.2%，调整后OR0.94，95%CI0.74-1.19）。
结论：既往接种流感疫苗与妊娠期间COVID-19严重程度降低或SARS-CoV-2感染几率降低无关。
目的：我们的主要目的是评估SARS-CoV-2感染者的流感疫苗接种是否与COVID-19严重程度、妊娠和新生儿结局相关。次要目标是检查流感疫苗接种与SARS-CoV-2感染之间的关联。
方法：对2020年3月至8月间SARS-CoV-2阳性孕妇的多中心回顾性队列和同期随机分娩队列进行二次分析。在2020年3月至8月期间，所有SARS-CoV-2检测呈阳性的人中，检查了2019年流感疫苗接种与中危COVID-19的主要结局以及孕产妇和围产期结局之间的关系。在2020年3月至8月之间随机选择的日期交付的一组个体中，检查了2019年流感疫苗接种与SARS-CoV-2测试阳性之间的关联。进行单变量和多变量分析。
结果：在SARS-CoV-2检测呈阳性的2325人中，有1068人（45.9％）在2019年接种了流感疫苗。接种流感疫苗的人年龄较大，leaner,更有可能有私人保险，并识别为白人或西班牙裔。他们吸烟的可能性较小，被认定为黑人。总的来说,419（18.0%）中度，193（8.3％）严重，和52（2.2%）关键COVID-19。流感疫苗接种与中度至重度COVID-19之间没有关联(29.2%与28.0%,校正OR1.10，95％CI0.90-1.34）或检测阳性的产妇和围产期不良结局。在2020年交付的8152人中，有4658人（57.1％）接种了流感疫苗。先前的疫苗接种与SARS-CoV-2感染几率的差异无关(3.8%与4.2%，调整后OR0.94，95%CI0.74-1.19）。
结论：既往接种流感疫苗与妊娠期间COVID-19严重程度降低或SARS-CoV-2感染几率降低无关。
